Alexion Pharmaceuticals, Inc. today announced the presentation of new data demonstrating the long-term benefits of Soliris® in patients with paroxysmal nocturnal hemoglobinuria , a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis .
